ES442579A1 - Procedimiento para preparar formulaciones de 1-dopa en uni- dades de dosificacion con revestimiento enterico-efervescen-te. - Google Patents

Procedimiento para preparar formulaciones de 1-dopa en uni- dades de dosificacion con revestimiento enterico-efervescen-te.

Info

Publication number
ES442579A1
ES442579A1 ES442579A ES442579A ES442579A1 ES 442579 A1 ES442579 A1 ES 442579A1 ES 442579 A ES442579 A ES 442579A ES 442579 A ES442579 A ES 442579A ES 442579 A1 ES442579 A1 ES 442579A1
Authority
ES
Spain
Prior art keywords
enteric coated
same
effervescent
dopa
dopa formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES442579A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interx Research Corp
Original Assignee
Interx Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interx Research Corp filed Critical Interx Research Corp
Publication of ES442579A1 publication Critical patent/ES442579A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procedimiento para preparar formulaciones de I-DOPA en unidades de dosificación con revestimiento entérico-efervescente, caracterizado porque en su realización comprende, en una primera etapa preparar una combinación pulverulante, según medios convencionales ya conocidos en el arte, formada por un componente activo seleccionado de L-DOPA o un derivado del mismo capaz de disociar y liberarL-DOPA in vivo, de la fórmula general **(Fórmula)** donde R y R1 significan simultáneamente los grupos hidroxilo acetiloxilo o pivaliloxilo, R2 representa hidrógeno, metilo, bencilo, pivaloloximetilo o un metal alcalino, de preferencia potasio, o bien, el grupo OR2 puede ser reemplazado por el radical -N-glicínico, cuando R y R1 significan acetiloxilo, X es un ácido farmacológicamente aceptable, de preferencia Hc1 o Hc1O4, o bien el grupo -XH puede esta substituido por clorhidrato de glicilo cuando R y R1 son acetiloxilo y R2 es hidrógeno o metilo, o bien puede esta substituido por el radical formilo.
ES442579A 1974-11-14 1975-11-13 Procedimiento para preparar formulaciones de 1-dopa en uni- dades de dosificacion con revestimiento enterico-efervescen-te. Expired ES442579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP49131304A JPS5157813A (en) 1974-11-14 1974-11-14 Ll dooba mataha sonojudotaiseizaino seiho

Publications (1)

Publication Number Publication Date
ES442579A1 true ES442579A1 (es) 1978-01-16

Family

ID=15054818

Family Applications (1)

Application Number Title Priority Date Filing Date
ES442579A Expired ES442579A1 (es) 1974-11-14 1975-11-13 Procedimiento para preparar formulaciones de 1-dopa en uni- dades de dosificacion con revestimiento enterico-efervescen-te.

Country Status (10)

Country Link
US (1) US3961041A (es)
JP (1) JPS5157813A (es)
CA (1) CA1047928A (es)
DE (1) DE2551280A1 (es)
ES (1) ES442579A1 (es)
FR (1) FR2290912A1 (es)
GB (1) GB1485676A (es)
IT (1) IT1069069B (es)
NL (1) NL7513370A (es)
SE (1) SE7512740L (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147768A (en) * 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
JPS54138128A (en) * 1978-04-19 1979-10-26 Akiyama Jiyouzai Kk Double contrast medium for intestine
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB2130087A (en) * 1982-09-22 1984-05-31 Dr Joachime Helbig Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
ES2232021T3 (es) * 1997-09-09 2005-05-16 Alza Corporation Composicion para recubrimiento farmaceutico y procedimiento de utilizacion.
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
DE69942205D1 (de) * 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
EP1137626A4 (en) 1998-11-10 2002-07-17 Teva Pharma METHOD FOR PRODUCING L-DOPA ETHYLESTER
JP2002529407A (ja) 1998-11-10 2002-09-10 テバ ファーマシューティカル インダストリーズ リミティド Ｌ−ｄｏｐａエチルエステル含有分散性組成物
KR100299562B1 (ko) 1998-12-29 2001-11-22 우재영 안정성을극대화시킨5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸유도체함유미세과립
AU2005202472B2 (en) * 1999-04-29 2008-12-18 Cima Labs Inc. Effervescent drug delivery system for oral administration
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
DE602004031771D1 (de) * 2003-12-31 2011-04-21 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
EP1708686B1 (en) * 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
JP2016029034A (ja) * 2014-07-18 2016-03-03 ナノメガ メディカル コーポレイションＮａｎｏｍｅｇａ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 医薬組成物
JP2017203031A (ja) * 2017-07-12 2017-11-16 スティッチング グロニンゲン セントル フォー ドラッグ リサーチ ｐＨ制御パルス送達システム、その調製法及び使用法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
FR2116256A1 (en) 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa

Also Published As

Publication number Publication date
JPS5157813A (en) 1976-05-20
SE7512740L (sv) 1976-05-17
FR2290912A1 (fr) 1976-06-11
FR2290912B1 (es) 1978-07-28
US3961041A (en) 1976-06-01
GB1485676A (en) 1977-09-14
CA1047928A (en) 1979-02-06
JPS5436645B2 (es) 1979-11-10
DE2551280A1 (de) 1976-05-20
IT1069069B (it) 1985-03-25
NL7513370A (nl) 1976-05-18

Similar Documents

Publication Publication Date Title
SE7512740L (sv) Sett att framstella en overdragen brusande l-dopaberedning som frigores i tarmen
PH12959A (en) Preparation of pharmaceutical unit dosage form
PH14489A (en) Manufacture of pharmaceutical dosage form
PH17318A (en) Manufacture of pharmaceutical unit dosage forms
AU498975B2 (en) Denture cleanser tablet
AU510235B2 (en) Denture cleanser tablet
IT7849462A0 (it) Corpo di capsula in particolare per una capsula per la somministrazione di sostanze medicamentose come pure procedimento e dispositivo per lasua produzione
PH13841A (en) Pharmaceutical preparation adapted for oral administration
NO140300C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (omega-1)-oksodialkylxantiner
PH13807A (en) Oral pharmaceutical preparation of esters testasterone
JPS51118839A (en) Amino acid pharmacy for liverish patient dosage
CS181182B2 (en) Vehiculum of medicament and method of its produce
ZA795530B (en) Pharmaceutical tablet for oral administration and process for its manufacture
IS3644A7 (is) Aðferð til að framleiða lyfjablöndu á formi smápilla til að meðhöndla þarmabólgur
ZA75530B (en) New derivatives of tyrosine having a pharmaceutical activity on smooth muscles
GB984464A (en) Therapeutic compositions comprising bromelain
PT65244B (en) Pharmaceutically active complexes and pharmaceutical compositions containing them
AU497698B2 (en) Administering gas toa patient
PH13199A (en) Methods and pharmaceutical preparation for the treatment of hypercholesterolaenia
AU7807175A (en) Analgesic formulations having enhanced therapeutic activity
NZ182046A (en) 9-0-ethers of clavulanic acid,saltd and esters and pharmaceutical compositions
NZ179078A (en) Ci-(aminomethyl)-naphthalene derivatives and pharmaceutical compositions
IL47334A (en) Pharmaceutical compositions for the treatment of parkinsonism, comprising l-dopa and cyproheptadine and their preparation
NZ184256A (en) Oral pharmaceutical compostions comprising certain esters of methicillin
NO143706C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-alkyl-7-(omega-1)-oksoalkylxantiner